The global market for point-of-care cholesterol monitoring devices is on the verge of substantial expansion, with a projected increase from USD 440.6 million in 2022 to USD 514.7 million by 2028, according to a recent survey conducted by Future Market Insights (FMI). This growth reflects a steady compound annual growth rate (CAGR) of 2.6% during the forecast period.
As cholesterol-related diseases continue to rise worldwide, the demand for convenient and efficient monitoring tools is experiencing a significant surge. Point-of-care cholesterol monitoring devices offer immediate and accurate readings, enabling patients and healthcare professionals to make informed decisions swiftly, thus driving market growth.
The increasing emphasis on preventive healthcare, combined with rapid advancements in diagnostic technology, is further fueling the adoption of point-of-care devices. These portable solutions empower individuals to monitor their cholesterol levels from the comfort of their homes or in clinical settings, effectively reducing the need for laboratory visits. This shift not only enhances accessibility but also supports proactive management of cardiovascular health.
“With the growing prevalence of cholesterol-related conditions, the market for point-of-care cholesterol monitoring devices is becoming increasingly vital,” said a FMI. “Our projections highlight a promising future for these innovative tools as they play a crucial role in enabling timely interventions and improving health outcomes.”
Key Market Drivers:
- Rising prevalence of cardiovascular diseases worldwide
- Increasing demand for at-home healthcare solutions
- Advancements in portable diagnostic technologies
With the healthcare industry shifting towards patient-centered care, the importance of accessible and easy-to-use monitoring solutions is expected to remain a key factor in the market’s growth trajectory.
Technological Advancements and Preventive Healthcare:
The integration of advanced technologies in healthcare, coupled with initiatives promoting preventive healthcare measures, is further bolstering the demand for point-of-care cholesterol monitoring devices. These devices empower healthcare professionals to perform on-the-spot testing, enhancing patient convenience and treatment efficacy.
Challenges and Market Constraints:
Despite the positive outlook, there are challenges impacting market growth. Concerns regarding accuracy and reliability, as well as regulatory hurdles, pose potential restraints. Point-of-care tests may not always match the accuracy of laboratory tests, and user errors can lead to result fluctuations. Additionally, stringent regulations for new device approval can cause delays and limit device variety, making healthcare providers and patients cautious in adopting these technologies.
Discover Market Trends: Access the Full Point-of-care Cholesterol Monitoring Device Market Report
Competitive Landscape:
The market for point-of-care cholesterol monitoring devices is dominated by a few major players, who frequently engage in strategic partnerships, product launches, and acquisitions to enhance their market presence. Recent developments include:
- In November 2019, ACON Laboratories, San Diego, CA, launched the On Call® Extra Mobile Glucose Monitoring Systems in Europe and Latin America.
- In April 2020, PTS Diagnostics partnered with MedPro Healthcare Sales Solutions, a leading healthcare contract sales organization.
Key Companies:
The market features several prominent companies, including:
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Abaxis, Inc. (a subsidiary of Zoetis Inc.)
- DiaSys Diagnostic Systems GmbH
- ACON Laboratories
- PTS Diagnostics
- Bioptik Technology, Inc.
- SD Biosensor, Inc.
- Jant Pharmacal Corporation, Inc.
- Nova Biomedical Corporation
- Beckman Coulter Inc. (a subsidiary of Danaher Corporation)
- SAMSUNG HEALTH CARE, Inc.
Market Segmentation:
The point-of-care cholesterol monitoring device market is segmented as follows:
- By Product: Instruments (Table-top Analyzers, Hand-held Analyzers), Testing Kits
- By Technology: Electrochemical Biosensor, Reflectance Photometry
- By Application: Dyslipidemia, Atherosclerosis, Hypercholesterolemia, Hypocholesterolemia, Others
- By End User: Hospitals, Diagnostics Centers & Laboratories, Ambulatory Surgical Centers, Home Care Settings
- By Region: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China & Japan (APECJ), China, Japan, Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
